SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VIDAMED-"FDA Approval Imminent" (VIDA)
VIDA 0.000010000.0%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: noronha who wrote (6)10/18/1996 2:50:00 AM
From: noronha   of 53
 
To: All
From: Noronha

I received on my fax machine today a "spot report" on VidaMed. Analyst Robert Faulkner of H&Q said that the stock sold off because there were people waiting to "sell into strength." However, he notes that they have finished their selling and expects VIDA to move sharply higher by year end. He expects heightened investor awareness as people start to realize the potential of treating enlarged prostates. With FDA approval they now have a significant lead time over any potential competitor. Furthermore, Johnson & Johnson recently invested in a little company in this area which lends more credibility and visibility to this emerging niche market.
Again, TUNA is more cost effective,safer and delivers better results than the current standard. The current standard can cause among other adverse side-effects retrograde ejaculation (sperm goes into bladder...YIKES!) In this cost conscious health care environment TUNA stands to gain enormously. The company should turn profitable in Q3 of '97 as revenues are just starting to explode. Finally, they will get favorable coverage and visibility at the H&Q Annual Healthcare Conference on January 6-9. His near-term target by the conference is $17-18. There are no guarantees but my money is where my mouth is. Comments welcome.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News